Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia

Francesco Lodola, Diego Morone, Marco Denegri, Rossana Bongianino, Hiroko Nakahama, Lucia Rutigliano, Rosanna Gosetti, Giulia Rizzo, Alessandra Vollero, Michelangelo Buonocore, Carlo Napolitano, Gianluigi Condorelli, Silvia G. Priori, Elisa Di Pasquale

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Catecholaminergic Polymorphic Ventricular Tachycardia type 2 (CPVT2) is a highly lethal recessive arrhythmogenic disease caused by mutations in the calsequestrin-2 (CASQ2) gene. We have previously demonstrated that viral transfer of the wild-type (WT) CASQ2 gene prevents the development of CPVT2 in a genetically induced mouse model of the disease homozygous carrier of the R33Q mutation. In the present study, we investigated the efficacy of the virally mediated gene therapy in cardiomyocytes (CMs) differentiated from induced pluripotent stem cells (iPSCs) obtained from a patient carrying the homozygous CASQ2-G112+5X mutation. To this end, we infected cells with an Adeno-Associated Viral vector serotype 9 (AAV9) encoding the human CASQ2 gene (AAV9-hCASQ2). Administration of the human WT CASQ2 gene was capable and sufficient to restore the physiological expression of calsequestrin-2 protein and to rescue functional defects of the patient-specific iPSC-derived CMs. Indeed, after viral gene transfer, we observed a remarkable decrease in the percentage of delayed afterdepolarizations (DADs) developed by the diseased CMs upon adrenergic stimulation, the calcium transient amplitude was re-established and the density and duration of calcium sparks were normalized. We therefore demonstrate the efficacy of the AAV9-mediated gene replacement therapy for CPVT2 in a human cardiac-specific model system, supporting the view that the gene-therapy tested is curative in models with different human mutations of CPVT.

Original languageEnglish
Article numbere2393
JournalCell Death and Disease
Volume7
Issue number10
DOIs
Publication statusPublished - Oct 6 2016

Fingerprint

Calsequestrin
Dependovirus
Cardiac Myocytes
Genetic Therapy
Induced Pluripotent Stem Cells
Mutation
Genes
Calcium Signaling
Viral Genes
Adrenergic Agents
Calcium
Polymorphic catecholergic ventricular tachycardia
Proteins

ASJC Scopus subject areas

  • Immunology
  • Cellular and Molecular Neuroscience
  • Cell Biology
  • Cancer Research

Cite this

Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia. / Lodola, Francesco; Morone, Diego; Denegri, Marco; Bongianino, Rossana; Nakahama, Hiroko; Rutigliano, Lucia; Gosetti, Rosanna; Rizzo, Giulia; Vollero, Alessandra; Buonocore, Michelangelo; Napolitano, Carlo; Condorelli, Gianluigi; Priori, Silvia G.; Di Pasquale, Elisa.

In: Cell Death and Disease, Vol. 7, No. 10, e2393, 06.10.2016.

Research output: Contribution to journalArticle

Lodola, Francesco ; Morone, Diego ; Denegri, Marco ; Bongianino, Rossana ; Nakahama, Hiroko ; Rutigliano, Lucia ; Gosetti, Rosanna ; Rizzo, Giulia ; Vollero, Alessandra ; Buonocore, Michelangelo ; Napolitano, Carlo ; Condorelli, Gianluigi ; Priori, Silvia G. ; Di Pasquale, Elisa. / Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia. In: Cell Death and Disease. 2016 ; Vol. 7, No. 10.
@article{c4432d58a1cb46c5af84d6c5bb08d7c2,
title = "Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia",
abstract = "Catecholaminergic Polymorphic Ventricular Tachycardia type 2 (CPVT2) is a highly lethal recessive arrhythmogenic disease caused by mutations in the calsequestrin-2 (CASQ2) gene. We have previously demonstrated that viral transfer of the wild-type (WT) CASQ2 gene prevents the development of CPVT2 in a genetically induced mouse model of the disease homozygous carrier of the R33Q mutation. In the present study, we investigated the efficacy of the virally mediated gene therapy in cardiomyocytes (CMs) differentiated from induced pluripotent stem cells (iPSCs) obtained from a patient carrying the homozygous CASQ2-G112+5X mutation. To this end, we infected cells with an Adeno-Associated Viral vector serotype 9 (AAV9) encoding the human CASQ2 gene (AAV9-hCASQ2). Administration of the human WT CASQ2 gene was capable and sufficient to restore the physiological expression of calsequestrin-2 protein and to rescue functional defects of the patient-specific iPSC-derived CMs. Indeed, after viral gene transfer, we observed a remarkable decrease in the percentage of delayed afterdepolarizations (DADs) developed by the diseased CMs upon adrenergic stimulation, the calcium transient amplitude was re-established and the density and duration of calcium sparks were normalized. We therefore demonstrate the efficacy of the AAV9-mediated gene replacement therapy for CPVT2 in a human cardiac-specific model system, supporting the view that the gene-therapy tested is curative in models with different human mutations of CPVT.",
author = "Francesco Lodola and Diego Morone and Marco Denegri and Rossana Bongianino and Hiroko Nakahama and Lucia Rutigliano and Rosanna Gosetti and Giulia Rizzo and Alessandra Vollero and Michelangelo Buonocore and Carlo Napolitano and Gianluigi Condorelli and Priori, {Silvia G.} and {Di Pasquale}, Elisa",
year = "2016",
month = "10",
day = "6",
doi = "10.1038/cddis.2016.304",
language = "English",
volume = "7",
journal = "Cell Death and Disease",
issn = "2041-4889",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia

AU - Lodola, Francesco

AU - Morone, Diego

AU - Denegri, Marco

AU - Bongianino, Rossana

AU - Nakahama, Hiroko

AU - Rutigliano, Lucia

AU - Gosetti, Rosanna

AU - Rizzo, Giulia

AU - Vollero, Alessandra

AU - Buonocore, Michelangelo

AU - Napolitano, Carlo

AU - Condorelli, Gianluigi

AU - Priori, Silvia G.

AU - Di Pasquale, Elisa

PY - 2016/10/6

Y1 - 2016/10/6

N2 - Catecholaminergic Polymorphic Ventricular Tachycardia type 2 (CPVT2) is a highly lethal recessive arrhythmogenic disease caused by mutations in the calsequestrin-2 (CASQ2) gene. We have previously demonstrated that viral transfer of the wild-type (WT) CASQ2 gene prevents the development of CPVT2 in a genetically induced mouse model of the disease homozygous carrier of the R33Q mutation. In the present study, we investigated the efficacy of the virally mediated gene therapy in cardiomyocytes (CMs) differentiated from induced pluripotent stem cells (iPSCs) obtained from a patient carrying the homozygous CASQ2-G112+5X mutation. To this end, we infected cells with an Adeno-Associated Viral vector serotype 9 (AAV9) encoding the human CASQ2 gene (AAV9-hCASQ2). Administration of the human WT CASQ2 gene was capable and sufficient to restore the physiological expression of calsequestrin-2 protein and to rescue functional defects of the patient-specific iPSC-derived CMs. Indeed, after viral gene transfer, we observed a remarkable decrease in the percentage of delayed afterdepolarizations (DADs) developed by the diseased CMs upon adrenergic stimulation, the calcium transient amplitude was re-established and the density and duration of calcium sparks were normalized. We therefore demonstrate the efficacy of the AAV9-mediated gene replacement therapy for CPVT2 in a human cardiac-specific model system, supporting the view that the gene-therapy tested is curative in models with different human mutations of CPVT.

AB - Catecholaminergic Polymorphic Ventricular Tachycardia type 2 (CPVT2) is a highly lethal recessive arrhythmogenic disease caused by mutations in the calsequestrin-2 (CASQ2) gene. We have previously demonstrated that viral transfer of the wild-type (WT) CASQ2 gene prevents the development of CPVT2 in a genetically induced mouse model of the disease homozygous carrier of the R33Q mutation. In the present study, we investigated the efficacy of the virally mediated gene therapy in cardiomyocytes (CMs) differentiated from induced pluripotent stem cells (iPSCs) obtained from a patient carrying the homozygous CASQ2-G112+5X mutation. To this end, we infected cells with an Adeno-Associated Viral vector serotype 9 (AAV9) encoding the human CASQ2 gene (AAV9-hCASQ2). Administration of the human WT CASQ2 gene was capable and sufficient to restore the physiological expression of calsequestrin-2 protein and to rescue functional defects of the patient-specific iPSC-derived CMs. Indeed, after viral gene transfer, we observed a remarkable decrease in the percentage of delayed afterdepolarizations (DADs) developed by the diseased CMs upon adrenergic stimulation, the calcium transient amplitude was re-established and the density and duration of calcium sparks were normalized. We therefore demonstrate the efficacy of the AAV9-mediated gene replacement therapy for CPVT2 in a human cardiac-specific model system, supporting the view that the gene-therapy tested is curative in models with different human mutations of CPVT.

UR - http://www.scopus.com/inward/record.url?scp=84990235360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990235360&partnerID=8YFLogxK

U2 - 10.1038/cddis.2016.304

DO - 10.1038/cddis.2016.304

M3 - Article

AN - SCOPUS:84990235360

VL - 7

JO - Cell Death and Disease

JF - Cell Death and Disease

SN - 2041-4889

IS - 10

M1 - e2393

ER -